Second Malignancies after Hematopoietic Stem Cell Transplantation
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Oncology
Link
http://link.springer.com/article/10.1007/s11864-018-0528-y/fulltext.html
Reference90 articles.
1. Gooley TA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091–101.
2. •• Shimoni A. Second malignancies after allogeneic stem cell transplantation with reduced-intensity conditioning: is the incidence reduced? Biol Blood Marrow Transplant. 2014;20(11):1669–70. This is our opinion of second malignancies after RIC is based on our single-center analysis. The records of 931 consecutive patients given allogeneic SCT with MAC (n = 257), RIC (n = 449) or RTC (n = 225), in a single institution over a 13-year period, were reviewed. Twenty-seven patients had secondary malignancy, diagnosed a median of 43 months (7 months–11.5 years) after SCT. This study is very important because it showed that the risk of secondary malignancies is not reduced and is even possibly increased in the era of fludarabine-based RIC/RTC.
3. Majhail NS, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18(3):348–71.
4. • Ringden O, et al. Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. Biol Blood Marrow Transplant. 2014;20(11):1777–84. In this study was examined risk of second solid cancers after allo-SCT using RIC/NMC for recipients with leukemia/MDS (n = 2833) and lymphoma (n = 1436) between 1995 and 2006. In addition, RIC/NMC recipients 40 to 60 years of age (n = 2138) were compared with patients of the same age receiving myeloablative conditioning (MAC, n = 6428). In this study the overall risks of second solid cancers in RIC/NMC recipients were similar to the general population, although there is an increased risk of cancer at some sites.
5. Armenian SH, et al. Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the bone marrow transplant survivor study (BMTSS) and childhood cancer survivor study (CCSS). Blood. 2011;118(5):1413–20.
Cited by 71 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Chimeric antigen receptor T-cell therapy for autoimmune diseases of the central nervous system: a systematic literature review;Journal of Neurology;2024-09-14
2. Re-examining the role of hematopoietic stem cell transplantation in relapsed large B-cell lymphoma in the era of chimeric antigen receptor (CAR) T-cell therapy;Frontiers in Oncology;2024-08-15
3. Diseases with oral malignant potential: Need for change to inform research, policy, and practice;Journal of Oral Pathology & Medicine;2024-08-05
4. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy;Nature Medicine;2024-07-08
5. Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma;Transplantation and Cellular Therapy;2024-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3